Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b study of retifanlimab (INCMGA00012), INCB001158, and their combination in Japanese participants with advanced solid tumors
jRCT2080224802Phase 1Completed
- Sponsor
- Incyte
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of retifanlimab and numidargistat in Nonhematologic neoplasms and solid tumor (3 arms), sponsored by Incyte. Primary endpoints: Recommended phase 2 dose (RP2D) of retifanlimab monotherapy, Recommended phase 2 dose (RP2D) of INCB001158 monotherapy and combination and 2 more. Started Jul 2019; status: completed.
02
Drugs
retifanlimabnumidargistat
03
Conditions
Nonhematologic neoplasmssolid tumor
Beyond the preview
Go deeper on jRCT2080224802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224802.